Diffuse Large B Cell Lymphoma Survival

For years, researchers have been looking for the right biomarkers to make the most accurate predictions of diffuse large B cell lymphoma survival rates among patients.

R-IPI as a Predictor of Diffuse Large B Cell Lymphoma Survival

One method for determining diffuse large B cell lymphoma survival in patientsis by using what is known as the Revised International Prognostic Index. The relative accuracy of this index has been supported by several subsequent studies. The R-IPI can be more closely examined at this page.

Call

Moleculor Expression as a Predictor for Diffuse Large B Cell Lymphoma Survival

Seeking prognostic indicators of value has not been easy for researchers, but according to the resuls of a paper published in 2009, at least one marker, found by way of pathologic techniques known as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

What they determined was that no single, individual protein marker found on cell surfaces (identified with CD placed before the number, such as "CD20") could be associated with diffuse large B cell lymphoma survival, and nor could two common chromosomal translocations, BCL-2 or c-MYC. However, the presence of the chromosomal translocation BCL-6 in fact does correlate with a poorer prognosis and poorer 5 year diffuse large B cell lymphoma survival rates than in patients with no BLC-6 translocation.

Sources

Sehn LH et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857-61.

Copie-Bergman C et al. Index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. . J Clin Oncol 2009 Sep 28.

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...